Background Adenosine deaminase (ADA) and carcinoembryonic antigen (CEA) have been measured in pleural fluid to help distinguish malignant from benign effusions, especially in tuberculous pleurisy. We investigated ADA and CEA levels in patients with moderate to large pericardial effusions of different etiologies.
Methods and Results We performed diagnostic and therapeutic pericardiostomy with drainage and biopsy. We measured ADA and CEA levels in the pericardial fluid in 26 patients with moderate to large pericardial effusion and 19 control patients. Patients were included in a prospective protocol from August 1991 to August 1993. Patients were grouped as follows: group 1, 9 patients with tuberculous pericarditis (TP) confirmed by bacteriologic culture or histology of pericardial biopsy; group 2, 5 patients with clinically strongly suspected TP; group 3, 12 patients with malignancy (8) and acute pericarditis (4); group 4, 19 control patients without pericardial disease. We treated patients with TP with isoniazid, rifampin, and either streptomycin or ethambutol for 12 months and pyrazinamide for 2 months. We observed for symptoms and signs of recurrent pericarditis or constrictive T he discovery that more than 50% of the white blood cells in an exudative pleural effusion are small lymphocytes is important diagnostically because it means that the patient probably has a malignant disease or tuberculosis.' Several studies have concluded that measurement of the carcinoembryonic antigen (CEA) level in pleural fluid is useful in establishing the diagnosis of malignant pleural effusions. '23 Measurement of the adenosine deaminase (ADA) level in pleural fluid is diagnostically useful because ADA levels tend to be higher in tuberculous pleural effusions than in other exudates. [2] [3] [4] [5] [6] It is difficult to establish a definitive bacteriologic diagnosis of tuberculous pericarditis because of several factors. The most difficult diagnostic case involves the patient with pericarditis in whom the PPD (purified protein derivative) test is positive but no tubercle bacilli are demonstrated in the pericardial fluid by histologic examination of the pericardium or elsewhere in the body in the absence of another cause of pericarditis. A few articles about the use of ADA assay in the diagnosis of tuberculous pericarditis have been reported,7-9 but comparison of the use of ADA assay in confirmed tuberculous pericarditis with that in clinically suspected tuberculous pericarditis has not yet been reported. Therefore, we investigated ADA and CEA levels in patients with moderate to large pericardial effusions of different etiologies.
Methods

Patients
In a systemic prospective protocol from August 1991 to August 1993, we measured the ADA and CEA levels in the pericardial fluid of 26 patients with pericarditis with moderate to large pericardial effusion on echocardiography for diagnostic and therapeutic pericardiostomy and biopsy. Moderate effusion was defined as echocardiographic evidence of anterior and posterior pericardial effusion and when the distance of the pericardial space was more than 15 mm on subcostal view during end diastole. All patients gave written informed consent for participation in the study, which was approved by the Ethics Committee of the Inha University Hospital.
Patients were grouped according to the diagnosis as follows: group 1, 9 patients with tuberculous pericarditis confirmed by demonstration of Mycobacterium tuberculosis by culture of pericardial fluid or pericardial tissue or caseous necrosis or granulomas on pericardial biopsy; group 2, 5 patients with clinically strongly suspected tuberculous pericarditis; group 3, 12 patients with acute pericarditis (4) or malignancy (7 with lung cancer and 1 with cervical cancer) by histologic examination; group 4, 19 control individuals without pericardial disease from whom pericardial fluid was obtained during cardiac surgery. We considered group 2 to be severely ill patients with (1) a hemorrhagic pericardial effusion, (2) a positive tuberculin skin test, (3) absence of a prodromal syndrome of an upper respiratory tract infection within the preceding weeks, (4) a negative workup for other causes of pericarditis, and (5) clinical improvement after initiation of antituberculosis chemotherapy after 10 to 14 days of admission. [10] [11] [12] Study Protocol
We performed diagnostic and therapeutic pericardiostomy with drainage and biopsy in all the patients of groups 1, 2, and 3. We checked total proteins, glucose, red blood cell and white blood cell number, differential cell count, lactic acid dehydrogenase, acid fast bacilli stained by the Ziehl-Neelsen method and cultured in Ogawa media and ordinary bacteria smears and cultures, cytology, and ADA and CEA from pericardial fluid of all the patients of groups 1, 2, and 3. Three sputum samples were stained by the Ziehl-Neelsen method and cultured in Ogawa media. Pathologists were blinded to the patients' ADA and CEA levels. 3 showed clinical and serological improvement without antituberculosis chemotherapy. After hospital discharge, the patients were followed up in the outpatient clinic every 2 months during the first 6 months, at 3-month intervals during the second 6 months, and subsequently at 6 months. Follow-up of group 1 patients ranged from 2 to 26 months (mean, 12.9 months), group There is considerable urgency in establishing the correct diagnosis so that appropriate treatment can be started. However, it is difficult to establish a definitive bacteriologic diagnosis of tuberculous pericarditis. The probability of obtaining a definitive diagnosis is greatest when pericardial fluid and a pericardial biopsy specimen are examined early in the effusive stage.7'9 However, it must be emphasized that a normal pericardial biopsy result does not exclude tuberculous pericarditis because in some patients, the examination of the entire pericardium removed at pericardiostomy or autopsy is required to demonstrate clear-cut evidence of tuberculosis.7,20 Moreover, constrictive pericarditis ultimately develops in almost all patients with untreated tuberculous pericarditis and in about half or less of patients who receive antituberculosis chemotherapy."112'
We believe that it may be necessary to make a presumptive clinical diagnosis of tuberculous pericarditis in strongly suspected patients living in endemic areas. In the era before antituberculosis therapy, tuberculous pericarditis was rapidly fatal, with an early mortality rate greater than 80%. Since the introduction of early chemotherapy, mortality from acute tuberculous pericarditis has fallen to less than 50%. However, it is very difficult to identify patients with tuberculous pericarditis. The most difficult diagnostic case involves the patient with pericarditis in whom tuberculous pericarditis is clinically strongly suspected but no tubercle bacilli are 
